Abstract

This article assesses Mexico’s organized crime alliance and subgroup network structures. Through social network…

This study finds that Maryland's all-payer model for healthcare comparatively lowered the risk of complications from surgery, as well as reducing increases in associated costs.

In this study, the authors found that a parental history of ACEs can weaken protective factors — such as resilience and social connections — that could mitigate the risk of perpetuating the trauma in the next generation.  Children and Youth Services Review: http://bit.ly/2UmOH95

The authors assess U.S. health care system and offer a plan for achieving universal health care. The Lancet: http://bit.ly/2lSaqX6

By Morgan N. Fredell, Hagop M. Kantarjian, Ya-Chen Shih, Vivian Ho and Binata Mukherjee Current U.S. health care spending includes many areas of wasted expenditures. In this study, published in Cancer, the authors explore plans to optimize U.S. health care to provide greater benefits to patients: https://bit.ly/2TmeoDg

Data from a survey of 892 scientists in Taiwan demonstrate that while scientists perceive religion and scientific research as generally separate in the abstract, in practice, they regard the boundary between religion and their workplace as somewhat permeable.

The authors examine whether Italian scientists have experienced any religious shifts and how they went through these shifts, addressing personal secularization theories by analyzing whether and how scientists reconstruct their religious identities by utilizing science. Published by Philosophy, Theology and the Sciences

Every patient with cancer or another life-threatening disease wants the most effective treatment, but drug prices have become staggering. What determines the escalating prices of cancer drugs?

For both generic and patented cancer drugs, the free-market economy has not worked well. Solutions are needed to maintain reasonable drug prices that allow for corporate profits and are affordable to patients and to the U.S. health care system.

In a genuine effort to protect patients from adverse events, regulatory burdens and research rigidity in clinical trials have increased to a point at which such protection is outweighing the benefits, and actually harming patients who are unable to be involved in clinical trials.